Literature DB >> 9073535

Blocking both E-selectin and P-selectin inhibits endotoxin-induced leukocyte infiltration into the eye.

S M Whitcup1, A T Kozhich, M Lobanoff, B A Wolitzky, C C Chan.   

Abstract

The initial contact between leukocytes and the vascular endothelium at sites of inflammation is mediated by selectins. The purpose of this study was to investigate the role of the two selectins expressed on the vascular endothelium, E-selectin and P-selectin, in the pathogenesis of endotoxin-induced uveitis. Endotoxin-induced uveitis was produced in female C3H/HeN mice using Salmonella typhimurium endotoxin injected into one hind footpad. At the time of endotoxin injection mice were treated with an intraperitoneal injection of a monoclonal antibody against E-selectin or P-selectin, a combination of both anti-selectin antibodies, or isotype-matched control antibodies. In a second set of experiments, antibody treatment was administered 6 hr after endotoxin injection, when inflammatory cells are already entering the eye. Ocular inflammation was graded histologically by a masked observer. When administered at the time of endotoxin injection, anti-P-selectin antibody decreased ocular inflammation by 37% compared to control animals (P = 0.05). There was no statistical decrease in ocular inflammation in animals treated with anti-E-selectin antibody. The combination of anti-P-selectin and anti-E-selectin antibodies decreased infiltrating inflammatory cells by 61% (P < 0.01). When treatment was delayed until 6 hr after endotoxin injection, the combination of anti-P-selectin and anti-E-selectin antibodies again decreased ocular inflammation by 60% (P < 0.01). Immunohistochemical staining showed decreased ICAM-1 expression in the eyes of animals treated with the combination of anti-P-and anti-E-selectin antibodies. Blocking both P-selectin and E-selectin resulted in a significant decrease in endotoxin-induced intraocular inflammation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9073535     DOI: 10.1006/clin.1996.4324

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  8 in total

Review 1.  Anterior uveitis: clinical and research perspectives.

Authors:  J T Rosenbaum; T M Martin; S R Planck
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.

Authors:  A D Dick; J D Isaacs
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

3.  Suppressive effects of selectin inhibitor SKK-60060 on the leucocyte infiltration during endotoxin induced uveitis.

Authors:  K Yamashiro; J Kiryu; A Tsujikawa; A Nonaka; K Nishijima; H Kamizuru; K Miyamoto; Y Honda; T Jomori; Y Ogura
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

4.  Effect of N-acetylcysteine on lipopolysaccharide-induced uveitis in rats.

Authors:  Xue-Yun Zhang; Seiji Hayasaka; Yoriko Hayasaka; Hu-Shan Cui; Zai-Long Chi
Journal:  Jpn J Ophthalmol       Date:  2007-02-09       Impact factor: 2.447

5.  Surprising up-regulation of P-selectin glycoprotein ligand-1 (PSGL-1) in endotoxin-induced uveitis.

Authors:  Lama Almulki; Kousuke Noda; Reza Amini; Alexander Schering; Rebecca C Garland; Shintaro Nakao; Toru Nakazawa; Toshio Hisatomi; Kennard L Thomas; Sharmila Masli; Ali Hafezi-Moghadam
Journal:  FASEB J       Date:  2008-12-02       Impact factor: 5.191

6.  Effects of the immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats.

Authors:  K Mangano; N Y Sardesai; C Quattrocchi; E Mazzon; S Cuzzocrea; K Bendtzen; P L Meroni; J J Kim; F Nicoletti
Journal:  Br J Pharmacol       Date:  2008-09-08       Impact factor: 8.739

Review 7.  Therapeutic targeting of STAT pathways in CNS autoimmune diseases.

Authors:  Charles E Egwuagu; Joseph Larkin Iii
Journal:  JAKSTAT       Date:  2013-01-01

Review 8.  Adhesion Molecule Targeted Therapy for Non-Infectious Uveitis.

Authors:  Yi-Hsing Chen; Sue Lightman; Malihe Eskandarpour; Virginia L Calder
Journal:  Int J Mol Sci       Date:  2022-01-03       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.